SAN.PA - Sanofi
| Previous Close | 79.09 |
| Open | 79.35 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 79.17 - 80.32 |
| 52 Week Range | 71.74 - 82.11 |
| Volume | 2,033,867 |
| Avg. Volume | 2,283,336 |
| Market Cap | 100.17B |
| Beta (3Y Monthly) | 0.44 |
| PE Ratio (TTM) | 28.07 |
| EPS (TTM) | 2.85 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | 3.07 (3.88%) |
| Ex-Dividend Date | 2019-05-09 |
| 1y Target Est | 82.62 |
- Reuters
Factbox: Britain's insulin providers prepare for Brexit fallout
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
- GlobeNewswire
Sanofi: information concerning the total number of voting rights and shares, August 2019
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and.
- GlobeNewswire
Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
– September 16, 2019 – Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies will take an innovative approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with insulin dosing information for future smart pens, insulin titration apps and cloud software.
- Investor's Business Daily
Popular Sanofi Heartburn Drug Could Contain Carcinogens, FDA Says
A commonly used heartburn medicine from Sanofi, known as Zantac, could contain cancer-causing substances, the Food and Drug Administration said Friday. Sanofi stock fell a fraction.
- TheStreet.com
FDA Says Sanofi's Zantac Medication Has Impurity That Could Cause Cancer
The FDA isn't calling for consumers to stop taking heartburn relief medicines with ranitidine 'at this time.'
- Benzinga
The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 10) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
- Reuters
Sanofi to pay Lexicon $260 mln for terminated partnership
Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista. Under the terms of the settlement, Sanofi will pay $208 million upfront and the remainder within twelve months to Lexicon, which was eligible to receive up to $1.4 billion in milestone payments under the partnership. The four-year partnership was terminated by Sanofi in July after the results of three late-stage studies of Zynquista, which is being developed as an add-on to insulin for diabetic patients.
- Reuters
UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Motley Fool
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?
It’s rejected a pair of drugs in the last six months.
- Moody's
L'Oreal U.S.A. Inc. -- Moody's affirms L'Oréal S.A.'s Prime-1 rating, stable outlook
Moody's Investors Service ("Moody's") has today affirmed the Prime-1 (P-1) short-term Commercial Paper ratings of both L'Oréal S.A. and its US subsidiary L'Oréal U.S.A. Inc. The outlook is stable. The affirmation of L'Oréal's Prime-1 (P-1) short-term Commercial Paper rating reflects the group's strong business profile, solid profitability and very strong credit metrics. Moody's expects the group's growth to continue to outperform the global beauty market.
- Motley Fool
Here's How Emergent BioSolutions Procured a Higher Price Today
The U.S. government wants more of its smallpox vaccine.
- Barrons.com
Sanofi Stock Is a Buy Because of Its Drug Pipeline, Analyst Says
Bernstein initiated coverage on Tuesday with an Outperform rating, saying that the company is well-positioned to succeed over the next few years.
- Simply Wall St.
What Kind Of Investor Owns Most Of Sanofi (EPA:SAN)?
Every investor in Sanofi (EPA:SAN) should be aware of the most powerful shareholder groups. Institutions will often...
- Investor's Business Daily
How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
- Reuters
UPDATE 2-Novartis takes aim at Roche's star MS drug
Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.
- GlobeNewswire
Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
August 28, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) are invalid based on lack of enablement. “It has been our longstanding belief that all of Amgen’s asserted U.S. PCSK9 patent claims are invalid, and we are pleased today’s decision reaffirms this,” said Karen Linehan, Executive Vice President and General Counsel, Sanofi.
- Reuters
U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U.S. biotech Regeneron from selling their drug Praluent. Repatha and Praluent won U.S. approval about two weeks apart in July of 2016.
- Benzinga
Biotech Stock On The Radar: MyoKardia Bets On Precision Medicine For Heart Health
MyoKardia Inc (NASDAQ: MYOK), a thinly traded mid-cap biotech, is on the radar of investors ahead of the company's scheduled presentation at the European Society of Cardiology Congress Aug. 31-Sept. 4 in Paris. The company is scheduled to present 36-week data from the PIONEER-OLE study — an open label extension study of the Phase 2 PIONEER study — that is evaluating its investigational drug and lead product candidate mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. Patients with oHCM are at an increased risk of heart failure, atrial fibrillation, stroke and death, including sudden cardiac death.
- Reuters
UPDATE 3-U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug. The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop French drugmaker Sanofi and U.S. biotech Regeneron from selling their drug Praluent.
- GlobeNewswire
Sanofi: information concerning the total number of voting rights and shares, July 2019
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article.
- Simply Wall St.
Does Sanofi's (EPA:SAN) CEO Pay Matter?
In 2015 Olivier Brandicourt was appointed CEO of Sanofi (EPA:SAN). First, this article will compare CEO compensation...
- Reuters
No-deal Brexit could deepen Europe's shortage of medicines - experts
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
Motley FoolMyoKardia, Inc. (MYOK) Q2 2019 Earnings Call Transcript
MYOK earnings call for the period ending June 30, 2019.
